Six-week Oral Drug Trial Produces High Hepatitis C Cure Rates

A recent clinical trial, published in The Lancet, involving a 6-week course of a combination of 3 direct-acting oral drugs was found to cure 38 of 40 individuals with hepatitis C virus infection (HCV).

The researchers had found that a 6-week course of therapy is actually half the length of time typically reported to achieve a similar, successful cure rate using only2 direct-acting oral HCV drugs.

For the clinical trial, the first group of 20 volunteers were administered a 6-week course of the newly licensed drug sofosbuvir (Sovaldi) coupled with 2 additional direct-acting oral therapies, ledipasvir and GS-9669 – an experimental drug. The second volunteer group also comprised of 20 individuals had received another 6-week course of sofosbuvir, ledipasvir, and a different experimental drug, GS-9451

. - See more at:

Labels: ,